Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Abuzar Moradi Tuchayi"'
Autor:
Surekha Yadav, Sarasa T. Kim, Abuzar Moradi Tuchayi, Fei Jiang, Amanda Morley, Rachelle Saelee, Yingbing Wang, Roxanna Juarez, Courtney Lawnh-Heath, Vadim S. Koshkin, Thomas A. Hope
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Purpose68Ga-PSMA-11 is recommended for the selection of patients for treatment in the package insert for 177Lu-PSMA-617. We aimed to compare imaging properties and post-treatment outcomes from radioligand therapy (RLT) of patients selected with 68Ga-
Externí odkaz:
https://doaj.org/article/eb08e626d53d4b5ba812584ec5be6b29
Autor:
Abuzar Moradi, Tuchayi, Nariman, Nezami, Yuchen, Zhang, Tarek N, Hanna, Jamlik-Omari, Johnson, Janice, Newsome, Sijian, Fan, Richard, Duszak, Elizabeth R, Benjamin, Jonathan, Nguyen, Michael A, Maceroli, April A, Grant, Deepika, Koganti, Laura K, Findeiss, Nima, Kokabi
Publikováno v:
Clinical Imaging. 86:75-82
To compare the clinical outcomes and trends of arterial embolization (AE) versus laparotomy which are used in the management of pelvic trauma.Adult patients with pelvic injuries were identified using the National Trauma Data Bank (NTDB) from 2007 to
Autor:
Payam Mehrian, Mohammad Ali Kazemi, Shahram Kahkouee, Ali Sabri, Arash Mahdavi, Mehrdad Bakhshayeshkaram, Sara Haseli, Farahnaz Falahati, Taraneh Faghihi Langroudi, Amir H. Davarpanah, Abuzar Moradi Tuchayi, Ali Mahdavi, Morteza Sanei Taheri
Publikováno v:
Journal of the American College of Radiology
Autor:
John M. Kirkwood, Hussein Tawbi, Melissa K. Yee, Nghi Nguyen, James M. Mountz, Abuzar Moradi Tuchayi
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
Frontiers in Oncology
Frontiers in Oncology
Introduction This pilot study aimed at exploring the utility of the proliferation tracer F-18 fluorothymidine (FLT) and positron-emission tomography (PET)/magnetic resonance imaging (MRI) (FLT–PET/MRI) for early treatment monitoring in patients wit
Publikováno v:
Blood. 124:5560-5560
INTRODUCTION: Myeloproliferative neoplasms (MPN) represent a significant risk for arterial and venous thrombosis. The JAK2 V617F mutation is an acquired mutation common in patients with polycythemia vera and essential thrombocythemia. Studies have sh